Edition:
India

Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

38.97USD
9:07pm IST
Change (% chg)

$-0.91 (-2.28%)
Prev Close
$39.88
Open
$39.75
Day's High
$39.78
Day's Low
$38.42
Volume
4,540,867
Avg. Vol
7,885,203
52-wk High
$46.46
52-wk Low
$34.38

About

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business... (more)

Overall

Beta: 0.99
Market Cap(Mil.): $214,682.30
Shares Outstanding(Mil.): 5,955.13
Dividend: 0.32
Yield (%): 3.55

Financials

  PFE.N Industry Sector
P/E (TTM): 26.26 29.30 32.55
EPS (TTM): 1.37 -- --
ROI: 6.00 14.23 13.83
ROE: 13.80 15.46 15.25

U.S., China key to GSK's consumer venture with Pfizer

LONDON The United States and China will be key focuses for the consumer healthcare venture being formed by GlaxoSmithKline and Pfizer, as the companies look to build on strong existing positions in those markets.

04 Apr 2019

U.S., China key to GSK's consumer venture with Pfizer

LONDON, April 4 The United States and China will be key focuses for the consumer healthcare venture being formed by GlaxoSmithKline and Pfizer, as the companies look to build on strong existing positions in those markets.

04 Apr 2019

Shareholder pushing for mandatory arbitration seeks to block J&J's annual meeting

There has been a significant escalation in the fight over whether corporations can require shareholders to arbitrate claims against the company.

28 Mar 2019

Pfizer buys stake in French gene therapy firm Vivet

Pfizer Inc said on Wednesday it acquired a 15 percent stake in Vivet Therapeutics, as well as an exclusive option to fully acquire it, a deal that will give it access to the French company's experimental gene therapy for a rare genetic disorder called Wilson disease.

20 Mar 2019

Pfizer buys stake in French gene therapy firm Vivet

Pfizer Inc said on Wednesday it acquired a 15 percent stake in Vivet Therapeutics, as well as an exclusive option to fully acquire it, a deal that will give it access to the French company's experimental gene therapy for a rare genetic disorder called Wilson disease.

20 Mar 2019

UPDATE 1-Pfizer buys stake in French gene therapy firm Vivet

March 20 Pfizer Inc said on Wednesday it acquired a 15 percent stake in Vivet Therapeutics, as well as an exclusive option to fully acquire it, a deal that will give it access to the French company's experimental gene therapy for a rare genetic disorder called Wilson disease.

20 Mar 2019

Pfizer buys stake in French gene therapy firm Vivet

March 20 Pfizer Inc said on Wednesday it has acquired a 15 percent stake in Vivet Therapeutics, and has an exclusive option to fully acquire the privately held French company that develops gene therapies for liver disorders.

20 Mar 2019

FDA approves Pfizer's biosimilar to Roche's Herceptin

The U.S. Food and Drug Administration said on Monday it approved Pfizer Inc's biosimilar to Roche AG's blockbuster breast cancer treatment Herceptin.

12 Mar 2019

UPDATE 1-FDA approves Pfizer's biosimilar to Roche's Herceptin

March 11 The U.S. Food and Drug Administration said on Monday it approved Pfizer Inc's biosimilar to Roche AG's blockbuster breast cancer treatment Herceptin.

12 Mar 2019

FDA approves Pfizer's biosimilar to Roche's Herceptin

March 11 The U.S. Food and Drug Administration said on Monday it approved Pfizer Inc's biosimilar to Roche AG's blockbuster treatment for breast cancer, Herceptin.

12 Mar 2019

Earnings vs. Estimates